Clinical Trials
9 trialsNCT05413018 2026-04-28
An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission
Bristol-Myers Squibb
Phase 2 Active not recruiting
NCT05197426 2026-02-11
A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Best Supportive Care as Maintenance Therapy in Japanese Participants With Acute Myeloid Leukemia (AML) in Complete Remission
Bristol-Myers Squibb
Phase 2 Active not recruiting
NCT01757535 2025-07-08
QUAZAR AML-001
Celgene
Phase 3 Completed
NCT04887857 2024-02-12
OMNIVERSE
Celgene
Phase 1 Completed
NCT03723135 2020-09-18
Expanded Access for CC-486
Celgene
Approved for marketing
NCT02223052 2020-05-12
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
Phase 1 Completed
NCT00528983 2019-11-08
Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia
Celgene
Phase 1 Completed
NCT01835587 2018-11-20
Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).
Celgene
Phase 1/2 Completed
NCT01908387 2015-07-28
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
Celgene
Phase 1 Terminated